Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The Company's lead in-licensed compound, emricasan, is being developed in collaboration with Novartis for the treatment of patients with NASH-driven chronic liver diseases. In addition, Conatus' lead internally developed compound, CTS-2090, is targeting the treatment of patients with chronic diseases involving inflammasome pathways. Source
No articles found.
Unique and disruptive, PatientDirected.io benefits the patient first. It intends t...
Unique and disruptive, PatientDirected.io benef...
Ocugen is a clinical stage biopharmaceutical company focused on discovering, devel...
Ocugen is a clinical stage biopharmaceutical co...
So-Young International Inc. (NASDAQ: SY) (âSo-Youngâ or the âCompanyâ) is ...
So-Young International Inc. (NASDAQ: SY) (âSo...
Vanda is developing important new medicines to improve the lives of patients. We u...
Vanda is developing important new medicines to ...
At ACADIA (NASDAQ: ACAD), we share a passion for improving the lives of patients w...
At ACADIA (NASDAQ: ACAD), we share a passion fo...
We are a leading science and technology company that delivers life-transforming me...
We are a leading science and technology company...
We are a clinical stage biopharmaceutical company focused on harnessing powerful b...
We are a clinical stage biopharmaceutical compa...
Join the National Investor Network and get the latest information with your interests in mind.